15th week of 2021 patent applcation highlights part 21 |
Patent application number | Title | Published |
20210107928 | SPHINGOSINE-1-PHOSPHATE ANALOG AND SYNTHESIS METHOD THEREFOR - The present specification relates to a sphingosine-1-phosphate (S1P) analogue and a method of synthesizing the same. A novel S1P analogue disclosed by the present specification is highly water-soluble and highly stable due to an alkoxyamine group thereof. Thus, the novel S1P analogue is suitable for use in manufacturing an immunodiagnostic kit. | 2021-04-15 |
20210107929 | DICARBONYL RUTHENIUM AND OSMIUM CATALYSTS - The disclosure relates to dicarbonyl complexes of ruthenium and osmium with bi- and tridentate nitrogen and phosphine ligands. The disclosure relates to methods for preparing these complexes and the use of these complexes, isolated or prepared in situ, as catalysts for reduction reactions of ketones and aldehydes both via transfer hydrogenation or hydrogenation with hydrogen. | 2021-04-15 |
20210107930 | Indacene Based Metallocene Catalysts Useful in the Production of Propylene Polymers - This invention relates homogeneous (typically solution) polymerization of propylene and optional olefin comonomer using metallocene catalyst compounds having a 1,5,6,7-tetrahydro-s-indacenyl moiety bridged to another indacenyl moiety or bridged to a substituted or unsubstituted indenyl moiety. | 2021-04-15 |
20210107931 | New potent sialyltransferase inhibitors - The present invention relates to a new class of sialyltransferase inhibitors. The class features a carbamate or similar moiety on the amine of a neuraminic acid derivative. Such inhibitors are suitable for use as a medicament, for example for treating, preventing, or delaying bacterial infection, viral infection, cancer, a disorder of sialic acid metabolism, or an autoimmune disease. | 2021-04-15 |
20210107932 | NEOMYCIN AND PAROMOMYCIN DERIVATIVES - The present disclosure relates to derivatives of neamine-based aminoglycoside antibacterial drugs modified in position C6′, C2′ and/or C5″. The modifications impart favorable properties regarding activity against ESKAPE pathogens, evasion of resistance traits and increased selectivity, enabling systemic use of the compounds. | 2021-04-15 |
20210107933 | HIGH-PURITY STEVIOL GLYCOSIDES - Methods of preparing highly purified steviol glycosides, particularly steviolmonoside, steviolmonoside A, steviolbioside, steviolbioside A, steviolbioside B, rubusoside, stevioside, stevioside A (rebaudioside KA), stevioside B, stevioside C, rebaudioside E, rebaudioside E2, rebaudioside E3, and rebaudioside AM are described. The methods include utilizing enzyme preparations and recombinant microorganisms for converting various staring compositions to target steviol glycosides. The highly purified rebaudiosides are useful as non-caloric sweetener, flavor enhancer, sweetness enhancer, and foaming suppressor in edible and chewable compositions such as any beverages, confectioneries, bakery products, cookies, and chewing gums. | 2021-04-15 |
20210107934 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS - The present invention relates to chemical linkers and protecting groups, compounds and compositions containing the chemical linkers or protecting groups, and intermediates and processes that can be used to prepare them. The chemical linkers and protecting groups are based on pyrrolidine and piperidine activating groups, which undergo intramolecular cyclisation upon heating with release of carbon dioxide, thereby releasing the organic compound from a substrate. In particular, those chemical linkers and protecting groups are useful in the solid phase synthesis of oligonucleotides according to the following representative schemes. | 2021-04-15 |
20210107935 | NOVEL, HEAVY VITAMIN B12 DERIVATIVES - The invention discussed in this application relates to vitamin B12-based compounds that are useful as quantitative standards, particularly for the assessment of vitamin B12 deficiency. | 2021-04-15 |
20210107936 | ENHANCED CRYSTAL NUCLEATION - Crystal nucleation, and associated articles, systems, and methods, are generally described. | 2021-04-15 |
20210107937 | SELECTIVE ENRICHMENT OF ANTIBODIES - The invention relates to a process for the selective concentration of immunoglobulins or other proteins that contain an Fc domain (target protein), comprising the following steps:
| 2021-04-15 |
20210107938 | POLYPEPTIDE SEPARATION METHOD, POLYPEPTIDE PRODUCTION METHOD, AND POLYPEPTIDE PURIFICATION DEVICE - The present invention relates to a polypeptide separation method including a step (step A) of mixing the polypeptide, which is a monoclonal antibody, and a ligand in a liquid to form a complex of the polypeptide and the ligand and to obtain a liquid containing the complex, and a step (step B) of filtering the liquid containing the complex obtained in the step A. | 2021-04-15 |
20210107939 | ANTIMICROBIAL COMPOUNDS - The present invention relates to a compound of formula (I) AA-AA-AA-R | 2021-04-15 |
20210107940 | 14-3-3 TARGETING PEPTIDES FOR CANCER TREATMENT - Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3ε heterodimerization or CDC25A binding to 14-3-3ε. A peptide composition embodiment includes, but is not limited to, at least one of a first targeting peptide comprising a structure of Trp-Tyr-Trp-Lys-NH | 2021-04-15 |
20210107941 | NOVEL CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-04-15 |
20210107942 | TISSUE PROTECTIVE PEPTIDES AND PEPTIDE ANALOGS FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE - The present invention provides peptides an peptide analogs that have tissue protective activities while having little or no potentionally undesirable hematopoietic effects. The peptides and peptide analogs are useful in preventing and treating a variety of diseases and disorders associated with tissue damage. | 2021-04-15 |
20210107943 | CO-ASSEMBLY PEPTIDES, NANOSTRUCTURES, AND METHODS OF MAKING AND USING THE SAME - Provided herein are charge complementary peptides that can be optionally coupled to a cargo polypeptide that are capable of self-assembling under stimulating conditions. The charge complementary peptides can be capable of forming supramolecular structures. Also provided herein are methods of using the charge complementary peptides provided herein. | 2021-04-15 |
20210107944 | COMPSTATIN ANALOGS FOR TREATMENT OF NEUROPATHIC PAIN - In some aspects, the present invention provides methods of treating a subject in need of treatment for neuropathic pain, the method comprising administering a compstatin analog to the subject. In some embodiments, the compstatin analog is administered parenterally, e.g., intravenously. | 2021-04-15 |
20210107945 | CHIMERIC INSECT-SPECIFIC FLAVIVIRUSES - Chimeric proteins that comprise one or more amino acid sequences of an insect-specific flavivirus and one or more other immunogenic proteins are provided. The chimeric proteins are suitably capable of forming virus particles. The chimeric protein and/or virus particle may be suitable for delivery to a subject to elicit an immune response to a pathogen and/or for diagnosis or detection of a pathogen. Also provided are nucleic acids and vectors encoding the chimeric proteins, and isolated chimeric insect-specific flaviviruses comprising the chimeric proteins and/or nucleic acids. | 2021-04-15 |
20210107946 | RECOMBINANT HERPES SIMPLEX VIRUS-2 EXPRESSING GLYCOPROTEIN B AND D ANTIGENS - The present invention is directed to Herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes. | 2021-04-15 |
20210107947 | MODIFIED VIRAL CAPSIDS - Methods for identifying polypeptides, e.g. derived from HSV pUL22 protein, which when displayed on a capsid confer a desired property to viral particles comprising such capsids, as well as methods for designing and manufacturing viral vectors and viral particles with improved properties. The identification method is based on a capsid library in which the capsid variant does not form part of the viral genome which contains a barcode and in which the barcode associated with the capsid variant is determined by sequencing before the viral vector is used. Thus, the prevalence of the capsid variant in a biological sample may be determined by sequencing of the barcode alone. | 2021-04-15 |
20210107948 | Hybrid Recombinant Adeno-Associated Virus Serotype Between AAV9 and AAVrh74 with Reduced Liver Tropism - The invention relates to a recombinant adeno-associated virus (AAV) capsid protein, which is a hybrid between AAV serotype 9 (AAV9) and AAV serotype 74 (AAVrh74) capsid proteins, wherein said recombinant hybrid AAV capsid protein has a reduced liver tropism compared to the parent AAV9 and AAVrh74 capsid proteins. The invention relates also to the derived hybrid AAV serotype vector particles packaging a gene of interest and their use in gene therapy, in particular for treating neuromuscular genetic diseases. | 2021-04-15 |
20210107949 | METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING LYMPHOCYTES TO EXPRESS POLYPEPTIDES COMPRISING THE INTRACELLULAR DOMAIN OF MPL - The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes. | 2021-04-15 |
20210107950 | ASTEXIN PEPTIDES - Provided are astexin-1, astexin-2 and astexin-3 lasso peptides, which are based on sequences identified in | 2021-04-15 |
20210107951 | PEPTIDES, ESPECIALLY POLYPEPTIDES, PHAGE DISPLAY SCREENING METHOD AND ASSOCIATED MEANS, AND THEIR USES FOR RESEARCH AND BIOMEDICAL APPLICATIONS - Disclosed are peptides, hosts expressing such peptides and a process for producing and screening such peptides or hosts. Also disclosed is use of the peptide or host expressing such peptide in the detection of disease, to a method for constructing a library of hosts, in particular of phages expressing peptides. Also disclosed is a library of hosts expressing peptides and its use for example for detecting molecules and/or cells in a sample, in the treatment of disease. These find application in the therapeutic and diagnostic medical technical fields. | 2021-04-15 |
20210107952 | BRASSICACEAE PROTEIN EXTRACT AND USES THEREOF - Methods of treating inflammation, in particular obesity, inducing satiation, prolonging satiety, and stimulating weight loss in a subject in need thereof, including the administration of a Brassicaceae protein extract. The Brassicaceae protein extract may be administered in the form of a dietary supplement or a food composition, either of which may include at least one additional ingredient. | 2021-04-15 |
20210107953 | ACTIVE POLYPEPTIDE COMPOUND - The present disclosure relates to the field of drug technology, specifically to an active polypeptide compound, which is Y-ID-X or X-ID-Y; wherein Y is a PTH/PTHrP receptor agonist or an osteoclast inhibitor; ID is a peptide bond or a linker in the molecule, which links X to Y; and X is an osteogenic growth peptide receptor agonist, a bone marrow mesenchymal stem cell irritant or a hematopoietic stem cell irritant. The present disclosure also relates to a pharmaceutical composition comprising the compound, and use of the compound and the pharmaceutical composition in the preparation of a medicament for preventing, treating or alleviating diseases or disorders related to osteogenic defects or bone mineral density decreasing. | 2021-04-15 |
20210107954 | Sericin Protein Particle with Oxidative Stress Property, Method for Preparing the Same and Use Thereof - The application relates to a sericin protein particle with an oxidative stress property, a method for preparing the same and use thereof. The particle is formed by sericin protein and a tellurium compound. In the method for preparing the sericin protein particle, bis(1-hydroxydodecyl) telluride is first prepared and then mixed with a solution of sericin protein, and a resulting solution is agitated continuously for some time to obtain telluride-modified sericin protein. Then, the solution of the sericin protein is added dropwise into absolute ethanol to obtain a precipitated product. An aqueous solution of the precipitated product and a solution of magnesium ions are mixed and agitated for a certain time to obtain the sericin protein particle with an oxidative stress property. The sericin protein particle disclosed is a hollow particle having a diameter in a range of 600-1250 nm, and is capable of loading biomacromolecule drugs or other components. | 2021-04-15 |
20210107955 | MUTANT MYC FUSION POLYPEPTIDES AND USES THEREOF - The present disclosure provides technologies for MYC inhibition, including, e.g. MYC fusion polypeptides and compositions comprising the same as well as methods of using the same. In particular, the present disclosure, among others, provides fusion polypeptides comprising a mutant MYC polypeptide and a repressor domain. In some embodiments, such fusion polypeptides and compositions comprising the same can be useful for inducing cancer cell apoptosis. Accordingly, in some embodiments, such fusion polypeptides and compositions comprising the same can be useful for cancer treatment. | 2021-04-15 |
20210107956 | ULTRASENSITIVE DETECTION PLATFORM USING LUMINESCENT METALS AND USES THEREOF - Polypeptides which comprises a plurality of luminescent metal binding sites and constructs comprising the polypeptides and bound luminescent metals are provided. When the constructs are exposed to suitable wavelengths of energy, the bound luminescent metals emit characteristic wavelengths of light. Thus, the constructs are used as luminescent tracking molecules e.g. as probes, markers, reporters, etc., and to deliver cargo to targeted cells or tissues. | 2021-04-15 |
20210107957 | CANCER ANTIGEN HELPER PEPTIDE - The present invention relates to a WT1 peptide which has an amino acid sequence consisting of contiguous amino acids derived from a WT1 protein and induces WT1-specific helper T cells by binding to an MHC class II molecule, a pharmaceutical composition comprising them and the like. | 2021-04-15 |
20210107958 | GLYPICAN EPITOPES AND USES THEREOF - The present invention relates to epitopes of glypican-1 (GPC-1) and uses thereof. | 2021-04-15 |
20210107959 | SINGLE-ARM CO-RECEPTOR FUSION PROTEINS AND USES THEREOF - In certain aspects, the disclosure provides single-arm heteromeric polypeptide complexes comprising an extracellular domain of a co-receptor of the TGF-beta superfamily. In some embodiments, the disclosure provides single-arm polypeptide complexes comprising an extracellular domain of a co-receptor selected from: endoglin, betaglycan, Cripto-1, Cryptic, Cryptic family protein 1B, Crim 1, Crim2, BAMBI, BMPER, RGM-A, RGM-B, MuSK, and hemojuvelin. Optionally the complex is a heterodimer. In certain aspects, such polypeptide complexes may be used for the treatment or prevention of various TGF-beta associated conditions, including without limitation diseases and disorders associated with, for example, cancer, muscle, bone, fat, red blood cells, metabolism, fibrosis and other tissues that are affected by one or more ligands of the TGF-beta superfamily. | 2021-04-15 |
20210107960 | FUSION PROTEIN, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PREPARING OPHTHALMIC DISEASE TREATMENT,ANTI-INFLAMMATION AND ANTI-TUMOR MEDICAMENT - The invention discloses a fusion protein, a preparation method thereof and application thereof in preparing ophthalmic disease treatment, anti-inflammation and anti-tumor medicament, and belongs to the field of biopharmaceutical technology. The present invention uses a flexible (F) or rigid (R) linker to fuse two polypeptides to respectively obtain two bifunctional fusion proteins, namely two multi-functional fusion protein macromolecules obtained by linking antiangiogenesis polypeptides HM-3, IL-4 and immunoglobulin Fc fragments via an amino acid linker, which can improve drug efficacy, prolong half-life and enhance stability, has the characteristics of strong effect, low toxicity and the like, and can be used for the prevention and treatment of solid tumors and various types of inflammations and neovascular ophthalmic diseases. The fusion protein is expressed in a eukaryotic cell by a genetic engineering method and purified by affinity chromatography or the like. | 2021-04-15 |
20210107961 | Fusion Protein Constructs Comprising an Anti-MUC1 Antibody and IL-15 - The present invention pertains to fusion protein constructs comprising an antibody against the cancer antigen MUC1 and IL-15. In particular, the fusion protein constructs activate NK cells and T cells at the cancer site. | 2021-04-15 |
20210107962 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF - The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure. | 2021-04-15 |
20210107963 | METHODS OF TREATMENT AND NOVEL CONSTRUCTS - The present invention provides novels method of targeting delivery of a compound to hypoxic cells, for example treatment of diseases and disorders associated with hypoxia, comprising administration of a construct comprising a targeting carrier peptide and a compound for delivery to a hypoxic cell. The invention also provides novel methods for the treatment of diseases or disorders of the eye by administration of a novel construct, a nucleic acid encoding a novel construct, and/or a nucleic acid vector comprising a nucleic acid encoding a novel construct. The invention further provides novel constructs, nucleic acids encoding such constructs, and/or nucleic acid vectors comprising nucleic acids encoding such constructs. | 2021-04-15 |
20210107964 | IMPROVED HINGE AREA AND USE OF SAME IN CONSTRUCTING CAR SKELETON - Provided in the present invention are an improved hinge area and the use of same in constructing CAR skeleton. The amino acid sequence of the improved hinge area is as shown in SEQ ID NO.1 or SEQ ID NO.2 or SEQ ID NO.3, and the hinge area can prolong the survival of CAR-T cells in vivo and/or improve the capability of CAR-T cells to infiltrate tumors. | 2021-04-15 |
20210107965 | BINDING-TRIGGERED TRANSCRIPTIONAL SWITCHES AND METHODS OF USE THEREOF - The present disclosure provides binding-triggered transcriptional switch polypeptides, nucleic acids comprising nucleotide sequences encoding the binding-triggered transcriptional switch polypeptides, and host cells genetically modified with the nucleic acids. The present disclosure also provides chimeric Notch receptor polypeptides, nucleic acids comprising nucleotide sequences encoding the chimeric Notch receptor polypeptides, and host cells transduced and/or genetically modified with the nucleic acids. The present disclosure provides transgenic organisms comprising a nucleic acid encoding a binding triggered transcriptional switch polypeptide and/or a chimeric Notch receptor polypeptide of the present disclosure. Binding triggered transcriptional switch polypeptides and chimeric Notch receptor polypeptides of the present disclosure are useful in a variety of applications, which are also provided. | 2021-04-15 |
20210107966 | NATURAL KILLER CELL PRODUCTS AND METHODS - The technology relates generally to the field of immunology and relates in part to compositions and methods for growing and storing modified natural killer cells, including for example, conditional chemical regulation of natural killer cell function. The technology further relates to pharmaceutical compositions and treatment of subjects using modified natural killer cells. | 2021-04-15 |
20210107967 | PRECISION ACTIVATION OF HIV-SPECIFIC CTLS TO ELIMINATE REACTIVATED LATENT T CELLS - Compositions and methods to increase the in vivo capacity of CD8+ T cells to kill HIV-infected and reactivated latent HIV-infected T cells (LHITC) to functionally cure HIV infection or improve the clinical course. Compositions and methods to increase the in vivo capacity of CD8+ T cells to kill CMV or CMV-infected cells are also provided. | 2021-04-15 |
20210107968 | FUSION PROTEIN, PREPARATION METHOD THEREFOR AND USE THEREOF - The invention discloses a fusion protein, preparation method thereof and use thereof and belongs to the field of biopharmaceutical technology. The fusion protein according to the present invention has anti-tumor, anti-autoimmune diseases and anti-inflammatory functions, and therapeutic effects on ophthalmic diseases. According to the long-acting, multifunctional fusion protein of the present invention, the EDSM-Y or EDSM-X polypeptide is fused to the antibody immunoglobulin Fc fragment by a flexible linker so as to obtain the fusion proteins I-V, which can improve the efficacy, prolong the half-life and enhance stability, have characteristics of strong effect, low toxicity and the like, and can be used for the prevention and treatment of solid tumors and various types of inflammation and neovascular ophthalmic diseases. The fusion protein is expressed in a prokaryotic cell or a eukaryotic cell by a genetic engineering method, and the expressed fusion protein is obtained by affinity chromatography. | 2021-04-15 |
20210107969 | MOLECULES, COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER - The present invention relates generally to the field of multifunctional fusion proteins to counteract immune dysfunction in the tumor microenvironment and more specifically to compositions and methods employing such fusion proteins (either alone or in combination regimens) for treatment of cancer. | 2021-04-15 |
20210107970 | DNA ANTIBODY CONSTRUCTS FOR USE AGAINST HIV - Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to an HIV antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an HIV infection in a subject using said composition and method of generation. | 2021-04-15 |
20210107971 | ANTI-ALPHA-SYNUCLEIN ANTIBODIES - The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease. | 2021-04-15 |
20210107972 | HUMAN ISLET AMYLOID POLYPEPTIDE (HIAPP) SPECIFIC ANTIBODIES AND USES THEREOF - Provided are novel human islet amyloid polypeptide, also known as amylin and IAPP and proIAPP respectively, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for IAPP and/or proIAPP are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for IAPP and/or proIAPP targeted immunotherapy and diagnostics, respectively. | 2021-04-15 |
20210107973 | GREMLIN-1 INHIBITOR FOR THE TREATMENT OF A BONE FRACTURE OR BONE DEFECT - The present invention relates to methods for the treatment of a bone fracture or bone defect. The invention discloses the effective use of an anti-gremlin-1 antibody to accelerate the healing and bridging of bone tissue in segmental gap defects; and demonstrates that inhibitors of gremlin-1 activity may provide improved therapies for treating or preventing fracture non-union. | 2021-04-15 |
20210107974 | Stabilized Formulations Containing Anti-NGF Antibodies - The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human nerve growth factor (hNGF). The formulations may contain, in addition to an anti-hNGF antibody, at least one non-ionic surfactant, at least one sugar, and acetate. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months. | 2021-04-15 |
20210107975 | ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE, AND/OR FEVER - The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved. | 2021-04-15 |
20210107976 | CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF - The present application provides immune cells (such as T cells) comprising a chimeric antibody-T cell receptor (TCR) construct (caTCR) and a chimeric signaling receptor (CSR) construct. The caTCR comprises an antigen-binding module that specifically binds to a target antigen and a T cell receptor module (TCRM) capable of recruiting at least one TCR-associated signaling molecule, and the CSR comprises a ligand-binding domain that specifically binds to a target ligand and a co-stimulatory signaling domain capable of providing a stimulatory signal to the immune cell. Also provided are methods of making and using these cells. | 2021-04-15 |
20210107977 | METHODS AND COMPOSITIONS FOR TREATING FIBROTIC DISEASES - The invention provides methods and compositions for the prevention or treatment of fibrotic diseases such as idiopathic pulmonary fibrosis and pre-fibrotic diseases such as chronic hypersensitivity pneumonitis. In particular, the invention provides methods for the prevention or treatment of fibrotic diseases and pre-fibrotic diseases through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention or treatment fibrotic diseases such as idiopathic pulmonary fibrosis and pre-fibrotic diseases such as chronic hypersensitivity pneumonitis. | 2021-04-15 |
20210107978 | CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITY - Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce. | 2021-04-15 |
20210107979 | DLL3 TARGETING CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS - Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs. | 2021-04-15 |
20210107980 | METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE - The invention provides an anti-PD-1 antibody in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer. | 2021-04-15 |
20210107981 | ANTI-PD-1 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-PD-1 ANTIBODIES AND METHODS OF USING ANTI-PD-1 ANTIBODIES - Provided herein are antibodies that selectively bind to PD-1 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods. | 2021-04-15 |
20210107982 | ANTIBODIES BINDING 4-1BB AND USES THEREOF - Disclosed is an isolated monoclonal antibody that specifically binds human 4-1BB, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present disclosure further provides a bispecific molecule, and a pharmaceutical composition comprising the antibody or the bispecific molecule, as well as a treatment method using an anti-4-1BB antibody of the disclosure. | 2021-04-15 |
20210107983 | MULTI-SPECIFIC BINDING PROTEINS FOR CANCER TREATMENT - The present invention relates to novel B7H6/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases. | 2021-04-15 |
20210107984 | Antibody which is Directed Against Galectin-9 and is an Inhibitor of the Suppressor Activity of Regulatory T Lymphocytes - The disclosure relates to an antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer. | 2021-04-15 |
20210107985 | HUMAN MONOCLONAL ANTIBODIES AGAINST CD25 - Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 2021-04-15 |
20210107986 | Methods of Treating Conditions with Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R) - Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis. | 2021-04-15 |
20210107987 | ANTI-CD20 ANTIBODY AND USES THEREOF - Provided herein are anti-CD20 antibodies and uses thereof for treatment and diagnosis. Also provided are CD20 antigens for the production of anti-CD20 antibodies and methods of generating anti-CD20 antibodies using the CD20 antigens. | 2021-04-15 |
20210107988 | POLYPEPTIDE VARIANTS AND USES THEREOF - The present invention relates to combination therapy involving two or more Fc region-containing antigen-binding polypeptides, such as antibodies, wherein the polypeptides have been modified such that hetero-oligomerization between the polypeptides is strongly favored over homo-oligomerization when the polypeptides are bound to their corresponding target antigens. The invention also relates to polypeptides, compositions, kits and devices suitable for use in the combination therapy of the invention. | 2021-04-15 |
20210107989 | METHODS FOR TREATING CD73HI TUMORS - Provided herein are, inter alia, 1E9 antibodies capable of binding CD73. The humanized antibodies are useful for the treatment of cancer in a subject expressing elevated levels of CD73. | 2021-04-15 |
20210107990 | NOVEL ANTI-PRESEPSIN ANTIBODY - The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies. | 2021-04-15 |
20210107991 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses - The present invention relates to subcutaneous formulations of anti-CD38 antibodies and their uses. | 2021-04-15 |
20210107992 | CONSTRUCTS SPECIFICALLY RECOGNIZING GLYPICAN 3 AND USES THEREOF - The present application provides constructs comprising an antibody moiety specifically recognizing Glypican 3 (GPC3), such as a cell surface-bound GPC3. Also provided are methods of making and using these constructs. | 2021-04-15 |
20210107993 | CARTYRIN COMPOSITIONS AND METHODS FOR USE - Disclosed are Centryin chimeric antigen receptors (CARTyrins), CARTyrin transposons encoding CARTyrins of the disclosure, cells modified to express CARTyrins of the disclosure, as well as methods of making and methods of using the same for adoptive cell therapy. In preferred embodiments, CARTyrins of the disclosure specifically bind to a sequence of prostate specific membrane antigen (PSMA). | 2021-04-15 |
20210107994 | MEDICINAL COMPOSITION USABLE FOR PREVENTING AND/OR TREATING BLOOD COAGULATION FACTOR IX ABNORMALITY, COMPRISING MULTISPECIFIC ANTIGEN BINDING MOLECULE REPLACING FUNCTION OF BLOOD COAGULATION FACTOR VIII - The present inventors examined the procoagulant activity of a multispecific antigen-binding molecule that functionally substitutes for FVIII using blood and plasma derived from FIX disorder patients. The result showed that multispecific antigen-binding molecules that functionally substitute for FVIII can be used not only as methods for preventing and/or treating bleeding in hemophilia A, acquired hemophilia A, von Willebrand disease, and hemophilia C, which are caused by FVIII dysfunction, but also as methods for preventing and/or treating bleeding in FIX disorders, because of their procoagulant activity. Furthermore, the effect of a FIX formulation could be enhanced by using it in combination with a multispecific antigen-binding molecule that functionally substitutes for FVIII, and it was shown that the combined use is promising as a combination therapy that shows stable hemostatic effects. | 2021-04-15 |
20210107995 | ANTIBODY SUBSTITUTING FOR FUNCTION OF BLOOD COAGULATION FACTOR VIII - The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII. | 2021-04-15 |
20210107996 | PLAP-CAR-EFFECTOR CELLS - The present invention is directed to a chimeric antigen receptor (CAR) fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) comprising V | 2021-04-15 |
20210107997 | ANTIBODY WITH NON-NATURAL AMINO ACID INTRODUCED THEREIN - The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof. | 2021-04-15 |
20210107998 | COMPOUND TARGETING IL-23A AND B-CELL ACTIVATING FACTOR (BAFF) AND USES THEREOF - The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed. | 2021-04-15 |
20210107999 | METHODS OF TREATING AN EYE DISORDER - Provided herein are methods of treating eye disorders by administering an anti-VEGF antibody and/or conjugate to a subject having an eye disorder. The anti-VEGF antibody of the present disclosure may be an anti-VEGF antibody conjugate that includes a polymeric moiety that extends the half-life/effectiveness/properties of the antibody when administered to a subject. A method of the present disclosure includes administering one or more doses of an anti-VEGF antibody conjugate to a subject (e.g., human or other mammalian patient) in need of treating an eye disorder, where the anti-VEGF antibody conjugate may be administered less frequently than a standard anti-VEGF therapy to treat the eye disorder. | 2021-04-15 |
20210108000 | DISINTEGRATED AND DECOMPACTED CELLULOSE-BASED VEGETABLE FIBRE MATERIALS USE AND METHOD FOR ACQUISITION AND PRODUCTION - The invention relates to separated, decompacted, cellulose-based fibres acquired from a vegetable raw material, wherein the separated, decompacted, cellulose-based fibres have an aspect ratio after soaking in water of longitudinal diameter to transverse diameter of 1:1 to 1000:1 and a water-binding capacity of >200 wt. % and a water retention capacity of >50%, and a method for acquiring and producing these separated, decompacted cellulose-based fibres. The purification method involves incubation of the vegetable material with an aqueous decomposition solution containing at least one dissolved amino acid and/or peptide with 2-50 amino acids to decompose the compacted cellulose-based fibres. | 2021-04-15 |
20210108001 | NANOCRYSTALLINE CELLULOSE, ITS PREPARATION AND USES OF SUCH NANOCRYSTALLINE CELLULOSE - The present invention relates to nanocrystalline cellulose, an efficient way of its preparation and to uses of such nanocrystalline cellulose. The present invention also relates to porous metal oxides having a chiral nematic structure which are prepared using nanocrystalline cellulose. | 2021-04-15 |
20210108002 | Purification Process For Capsular Polysaccharide - Purification methods suitable for purification of bacterial capsular polysaccharides from | 2021-04-15 |
20210108003 | Method for Isolating Cellulose- or Chitin-Nanocrystals by Means of Periodate Oxidation - For the isolating of nanocrystals from a lignocellulose- or chitin-containing starting material, the starting material is exposed to an oxidative effect of periodate anions in an aqueous suspension. The pH value of the aqueous suspension is adjusted to greater than pH 7.0. The periodate anions are provided in a quantity of at least 5 mol per kg of the starting material, and the starting material is exposed to the oxidative effect of the periodate anions in the aqueous suspension for a period of at least one day. | 2021-04-15 |
20210108004 | STABLE IRON OLIGOSACCHARIDE COMPOUND - The invention relates to n iron oligosaccharide compound with improved stability comprising a hydrogenated oligosacharride in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia. | 2021-04-15 |
20210108005 | HIGHLY SOLUBLE BIS-BORATE AS BINUCLEAR CO-CATALYSTS FOR OLEFIN POLYMERIZATION - Embodiments are directed to catalyst systems comprising: a procatalyst; and a co-catalyst dissolved in a non-halogenated aprotic hydrocarbon solvent, the co-catalyst comprising: a non-coordinating borate dianion having the formula: (III) and two cations, each cation being independently chosen from a cation according to formula (I) or formula (II). | 2021-04-15 |
20210108006 | BORATE-ACTIVATED METALLOCENE CATALYSTS - Catalyst system, the catalyst system comprising (i) at least one metallocene complex of formula (I), (I) wherein Mt1 is Hf, X is a sigma-donor ligand, R | 2021-04-15 |
20210108007 | PROCESS FOR REDUCING THE VOC CONTENT OF PLASTOMERS - The present invention relates to a process for reducing the volatile organic compound (VOC) content of plastomers the process comprising the steps of subjecting the plastomer in granular form containing VOCs which is contained in an aeration vessel to a gasflow, and withdrawing granular plastomer from the aeration vessel which has a lower content of VOCs, wherein the average particle size of the granular plastomer is greater than 2.5 mm, preferably greater than 2.7 mm, more preferably greater than 3.0 mm, wherein the gas has a minimum temperature of at least 26° C. measured at a gas inlet of the aeration vessel, and a maximum temperature of 4° C. below the Vicat temperature (10N, ISO 306) of the granular plastomer or 35° C. measured at the gas inlet of the aeration vessel, whatever value is lower, and wherein at least a part of the withdrawn granular plastomer is recirculated to the aeration vessel. | 2021-04-15 |
20210108008 | PRODUCTION METHOD FOR FLUOROPOLYMER, SURFACTANT FOR POLYMERIZATION, AND USE OF SURFACTANT - A method for producing a fluoropolymer of the invention which includes polymerizing a fluoromonomer in an aqueous medium in the presence of a surfactant to provide a fluoropolymer. The surfactant includes at least one selected from the group consisting of a surfactant represented by R | 2021-04-15 |
20210108009 | METHOD FOR PRODUCING ALICYCLIC ACRYLATE DERIVATIVE - Provided is a composition including an alicyclic acrylate derivative. A composition including an alicyclic acrylate derivative according to one embodiment of the present invention includes an alicyclic acrylate compound but does not include an amine derivative by-product. | 2021-04-15 |
20210108010 | SYSTEMS AND PROCESSES FOR POLYACRYLIC ACID PRODUCTION - Disclosed are systems and methods for the production of polyacrylic acid and superabsorbent polymers from ethylene oxidation to form ethylene oxide. Reacting the ethylene oxide with carbon monoxide to form to beta propiolactone (BPL) or polypropiolactone (PPL), or a combination thereof. An outlet configured to provide a carbonylation stream comprising the BPL or PPL, or a combination thereof and using one or more reactors to convert BPL to acrylic acid or to convert at least some of the BPL to PPL, and then to convert PPL to acrylic acid. An outlet configured to provide a PPL stream to a second reactor tm to convert at least some of the PPL to AA or a third reactor to convert at least some of the PPL to AA. The outlet configured to provide an AA stream to a fourth reactor to convert the AA to polyacrylic acid. | 2021-04-15 |
20210108011 | FLUORINATED THERMOPLASTIC ELASTOMERS - The invention pertains to novel fluorinated thermoplastic elastomers, including PCTFE-like plastomeric blocks, contributing substantially to the improvement of sealing performances upon increasing temperature of the fluorinated thermoplastic elastomers comprising the same. | 2021-04-15 |
20210108012 | CURABLE COMPOSITION, CURED PRODUCT, OPTICAL MEMBER, LENS, AND COMPOUND - The present invention provides a curable composition containing a compound represented by General Formula A and a compound represented by General Formula B. | 2021-04-15 |
20210108013 | WATER-SOLUBLE COPOLYMERS - Water-soluble copolymers based on
| 2021-04-15 |
20210108014 | COMPOSITION-CONTROLLED POLYMERS, METHODS OF FORMATION, AND USES THEREOF - A composition of matter includes a mixture of styrene derivative monomers and methacrylate/acrylate derivative monomers, which form hydrogen bonds between/among different precursors, and initiators, and the compositions are used to achieve composition control of the forming polymer, with the mole fraction of acrylate/methacrylate and styrene moieties in the forming polymer determined preferably by the monomer reactivity and monomer composition rather than the viscosity of the monomers. | 2021-04-15 |
20210108015 | PREFORMED STABILIZERS WITH IMPROVED STABILITY - This invention relates to novel preformed stabilizers in which a portion of the polymer control agent is recovered and comprises from 10 to 1500 ppm of an inhibitor. This invention also relates to a process for preparing these preformed stabilizers, and to polymer polyols comprising these novel preformed stabilizers macromers and to a process for preparing polymer polyols comprising these novel preformed stabilizers. The present invention also relates to polyurethane foams comprising these polymer polyols, and to processes for preparing these polyurethane foams. | 2021-04-15 |
20210108016 | MODIFIED POLYPROPYLENE RESIN AND METHOD FOR PRODUCING SAME, AND EXTRUDED FOAM PARTICLES THAT USE SAID MODIFIED POLYPROPYLENE RESIN AND METHOD FOR THEIR PRODUCTION - A novel modified polypropylene resin is provided which makes it possible to provide, by an extrusion expansion method, expanded polypropylene-based resin particles having an expansion ratio which falls within a wide range and having a low open cell ratio. The novel modified polypropylene resin is obtained by a method of producing the modified polypropylene resin where the method includes a melting and kneading step of melting and kneading a particular random polypropylene resin, a conjugated diene compound, and a particular radical polymerization initiator to obtain the modified polypropylene resin. | 2021-04-15 |
20210108017 | (CO)POL YMERS OF HYDROPHOBIC MONOMERS AND METHODS OF MAKING AND USE THEREOF - Described herein are methods of making a composition, the method comprising polymerizing monomers comprising a hydrophobic monomer in the presence of a solid grade oligomer, thereby forming a (co)polymer derived from the hydrophobic monomer, wherein the (co)polymer is derived from 5% by weight to 100% by weight of the hydrophobic monomer based on the total monomer weight. The hydrophobic monomer has a solubility in water of 0.2 g/100 g or less as measured at 20° C. The hydrophobic monomer comprises a substituted or unsubstituted C | 2021-04-15 |
20210108018 | ALL-ACRYLIC MULTIGRAFT COPOLYMER SUPERELASTOMERS - Thermoplastic elastomer compositions comprising acrylic multigraft copolymers are described. The multigraft copolymers comprise a rubbery polyacrylate backbone and a plurality of randomly spaced glassy polyacrylate side chains. The multigraft copolymers can be prepared using a facile grafting through method that can provide copolymers with enhanced purity. The acrylic multigraft copolymers exhibit microphase separated morphologies and “superelastomeric” properties, including an elongation at break, strain at break, and/or strain recovery behavior that exceeds that of conventional triblock copolymer polyacrylate thermoplastic elastomers. | 2021-04-15 |
20210108019 | AQUEOUS DISPERSIONS INCLUDING POLYESTER PARTICLES, PHOTOPOLYMERIZABLE COMPOSITIONS, ARTICLES, AND METHODS - The present disclosure provides an aqueous dispersion. The aqueous dispersion includes a) water; b) a surfactant having at least one ethylenically unsaturated group; and c) polyester particles dispersed in the water. The polyester particles include a water-insoluble polyester having a weight average molecular weight of 20 kiloDaltons or greater, and the polyester particles have an average diameter that is submicron in size. Further, the present disclosure provides a method of making the aqueous dispersion. The method includes a) dissolving a water-insoluble polyester in a water-immiscible solvent to form a polyester solution; b) combining the polyester solution with an aqueous solution including water and a surfactant; and c) removing at least a portion of the water-immiscible solvent to form the aqueous dispersion including polyester particles dispersed in the water. The present disclosure also provides a photopolymerizable composition including a) water; b) a surfactant; c) polyester particles dispersed in the water; d) a photoinitiator; e) at least one ethylenically unsaturated monomer dispersed in the water; and f) an optional polymerization inhibitor. The present disclosure also provides coatings and articles prepared from the aqueous dispersion or photopolymerizable composition. | 2021-04-15 |
20210108020 | POLYURETHANE PREPOLYMER COMPOSITION, AND POLYURETHANE ELASTOMER AND METHOD FOR PREPARING THE SAME - A polyurethane prepolymer composition is provided. The polyurethane prepolymer composition includes a first prepolymer, a second prepolymer and a third prepolymer. The first prepolymer includes a polyol and diisocyanates. The two ends of the polyol are connected with the diisocyanates. The second prepolymer includes a diisocyanate monomer. The third prepolymer includes a first diisocyanate, polyols and second diisocyanates. The two ends of the first diisocyanate are connected with the polyols. The other ends of the polyols are connected with the second diisocyanates. A polyurethane elastomer and a preparation method thereof are also provided. | 2021-04-15 |
20210108021 | SOLID SURFACE MATERIALS WITH POLYURETHANE MATRIX - The present invention relates to polyurethane based solid surface materials with improved dimensional stability which can be made using conventional inorganic fillers without pre-treatment of the fillers. | 2021-04-15 |
20210108022 | Sprayable Marine Foam - The invention generally pertains to the use of polyurethane foam blown by at least one blowing agent having a boiling point at atmospheric pressure of between ˜−50° C. to less than ˜5° C., including miscible blends thereof, which passes all United States Coast Guard Title 33, Part 183 specifications wherein the buoyant force of the froth polyurethane or polyisocyanurate foam is not reduced more than 5% after exposure to being immersed in a fully saturated gasoline vapor atmosphere, in reference fuel B, in reference oil No. 2, and in a 5% solution of Na | 2021-04-15 |
20210108023 | FLEXIBLE COATING COMPOSITION - The present disclosure describes polymers and improved resin systems having flexibility, low water uptake, good adhesion, chemical resistance, and/or weatherability at extreme negative temperatures, such as temperatures down to about −40° C. or below and even temperatures down to about −60° C. The systems herein, in approaches, include a polymer or resin system for an epoxy component of an epoxy/amine system including an epoxy and/or acetoacetoxy functionalized flexible block copolymer that has a base hydrophobic polyol block or core, optional flexible monomeric blocks, and epoxy, acetoacetoxy, or both functional endcaps. | 2021-04-15 |
20210108024 | USE OF EPOXIDIZED SOY FATTY ACID ESTERS AS REACTIVE DILUENTS AND MODIFIERS IN EPOXY COATINGS AND RESINS - An epoxy resin composition is provided which comprises an epoxy resin and a reactive diluent comprising one or more of the monoesters of epoxidized soy oil characterized by a ratio of mols of epoxide groups to mols of ester on the whole of at least 1.35:1. A thermoset plastic composition is also provided which comprises an epoxy resin composition as described, with an amine curing agent. | 2021-04-15 |
20210108025 | EPOXY RESIN COMPOSITION - An epoxy resin composition includes at least one thiol-based curing agent, a main epoxy resin, and a curing catalyst. The at least one thiol-based curing agent includes a non-hydrolyzable polyfunctional thiol compound having at least one hydroxyl group and/or urea bond. The main epoxy resin is at least one main aliphatic polyfunctional epoxy resin selected from a polyethylene glycol diglycidyl ether, a cyclohexane-based diglycidyl ether, and a dicyclopentadiene-based diglycidyl ether. The epoxy resin composition has a viscosity at 25° C. of 0.05 Pa·s or higher and 3 Pa·s or lower | 2021-04-15 |
20210108026 | COMPOSITIONS CONSISTING OF BRONSTED ACIDS AND MONOAMINES - The present invention provides compositions consisting of a) at least one metal salt, ammonium salt or phosphonium salt of a strong Brønsted acid and b) at least one primary aliphatic monoamine, processes for preparation thereof and use thereof. | 2021-04-15 |
20210108027 | POLYESTER RESIN FOR HEAT-SHRINKABLE FILM, HEAT-SHRINKABLE FILM, HEAT-SHRINKABLE LABEL, AND PACKAGED PRODUCT - The invention provides a polyester resin for heat-shrinkable film which contains terephthalic acid as a main component of a dicarboxylic acid component, contains ethylene glycol as a main component of a diol component, and contains from 18 to 32% by mol of neopentyl glycol and from 8 to 16% by mol of diethylene glycol when a total amount of the whole diol component in total polyester resin components is taken as 100% by mol. The polyester resin has an intrinsic viscosity (IV) of from 0.70 to 0.86 dl/g, a carboxyl end group concentration (AV) of from 8 to 25 eq/t, and a color b value of from 1.0 to 12.0 in an L*a*b color system. The invention also provides a heat-shrinkable film prepared from the aforementioned polyester resin, as well as a heat-shrinkable label and packaged product. | 2021-04-15 |